Ascendia Pharmaceuticals' Nanoemulsion IV Formulation for Clopidogrel Granted IND Approval
Ascendia Pharmaceuticals' has announced a significant achievement in the development of a novel nanoemulsion IV formulation for clopidogrel. This innovative formulation, utilizing Ascendia's patented EmulSol® nanotechnology, has received Investigational New Drug (IND) approval from the FDA. The partnership between Ascendia Pharmaceuticals and AcuteBio, LLC has played a crucial role in the formulation's success
The primary objective of this formulation is to improve the treatment of coronary artery disease (CAD), particularly in stent placements. Unlike the oral dosing method with a delayed onset of action, the IV delivery of clopidogrel allows for immediate effectiveness. This enables quicker stent insertion and more efficient removal of blockages. The FDA's IND approval validates the effectiveness of Ascendia Pharma's EmulSol technology platform.
This accomplishment marks a significant milestone as previous attempts by other pharmaceutical companies to develop a clopidogrel IV formulation have been unsuccessful. Ascendia Pharmaceuticals' success is a testament to their commitment to making the impossible possible through the utilization of their nanotechnologies.
EmulSol is one of the four proprietary nanotechnology platforms developed by Ascendia Pharmaceuticals. The other platforms include AmorSol®, NanoSol®, and LipidSol®, all of which have proven their effectiveness in overcoming challenges related to bioavailability, solubility, and stability. These nanotechnologies provide valuable advantages in drug development and contribute to Ascendia Pharmaceuticals' reputation as a leading specialty CDMO (Contract Development and Manufacturing Organization).
